|
|
|
Age : 59 Public asset : 7,932,901 USD Country of residence : Unknown Linked companies :  Exelixis, Inc. |
|
|
| Currently, Peter Lamb occupies the position of Chief Scientific Officer & EVP-Scientific Strategy at Exelixis, Inc.
He previously was Director-Transcription Research at Ligand Pharmaceuticals, Inc.
Dr. Lamb received a doctorate from the University of London and an undergraduate degree from the University of Cambridge.
|
| Current positions of Peter Lamb | |
|
| Name | Title |
Since |
Exelixis, Inc.
(Biotechnology & Medical Research) |
Chief Scientific Officer & EVP-Scientific Strategy |
2016 |
|
|
|
| Name | Equities | % | Valuation |
Exelixis, Inc. (EXEL)
(Biotechnology & Medical Research) | 357,177 | 0.12% | 7,932,901 USD |
|
| Peter Lamb : Personal Network | |
|
| Name | Linked companies |
| Alan M. Garber | Exelixis, Inc. |
| Carl B. Feldbaum | Exelixis, Inc. |
| Jack L. Wyszomierski | Exelixis, Inc. |
| Gisela Schwab | Exelixis, Inc. |
| George H. Poste | Exelixis, Inc. |
| Charles M. Cohen | Exelixis, Inc. |
| Stelios Papadopoulos | Exelixis, Inc. |
| Lance Willsey | Exelixis, Inc. |
| Michael Morrissey | Exelixis, Inc. |
| Vincent T. Marchesi | Exelixis, Inc. |
|
© 2021 People and Ownership : 
|
|
|
| Latest news about Peter Lamb | |
|
|
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
